EUVIMEDObjevte EUVIMED
Open access

A survey of cystic fibrosis physicians' views on lung transplant referral in the era of elexacaftor/tezacaftor/ivacaftor

Nora Burdis iD, Tijana Milinic, Lauren E Bartlett, Louisa Goss, Erin Tallarico, Abigail Boyle, Abigail Thaxton, Grant A Turner, Luke J Benvenuto, Albert Faro, Christopher H Goss, Siddhartha G Kapnadak and 1 more

Pediatric Pulmonology · 2024

DOI: 10.1002/ppul.27273 ↗

At a glance

Journal article in Pediatric Pulmonology, 2024. Written by Nora Burdis and 12 co-authors. Institution: Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA. Major MEDLINE topics: Cystic Fibrosis, Lung Transplantation, Benzodioxoles, Referral and Consultation. Cited 2 times so far (Crossref); 17 references. The full text is freely available in PubMed Central. Funded by: NIH HHS, NIDDK NIH HHS, Cystic Fibrosis Foundation.

AbstraktSubjectsBibliografické údajeCiteRelated studies

Abstract (original language)

Rationale

In 2015, a survey of cystic fibrosis (CF) physicians showed significant gaps in lung transplant (LTx) referral knowledge. Subsequently, LTx referral guidelines for people with CF were published, and elexacaftor/tezacaftor/ivacaftor (ETI) became available for >80% of people in the United States (US). We sought to assess physicians’ LTx referral knowledge and self‐reported referral practices.

Methods

CF center directors in the US were surveyed about LTx. Questions addressed transplant referral indications, contraindications, testing, and the impact of ETI on referral timing. Thematic analysis was used to assess responses to open‐ended questions.

Results

There were 110/309 (36%) responses. Respondents identified several referral indications, including rapid decline in FEV 1 (93%), recurrent hemoptysis (80%), hypoxemia (79%), and pulmonary hypertension (75%). Over 70% of respondents reported using oximetry, echocardiogram, and blood gas to assess disease severity. Respondents were more likely to find early LTx discussions useful for patients not on modulators versus on modulators (87% vs. 63%, p < .005). Most respondents (66%) reported delaying LTx referral for some patients with FEV 1 30%–40% who met criteria, while 26% had delayed referral for patients with FEV 1 < 30%. Uncertainty regarding optimal LTx referral timing for patients on ETI was a prominent theme of the qualitative analysis.

Conclusions

While physician knowledge about LTx referral indications appears improved since the CF referral guidelines were published, uncertainty about referral timing is pervasive, and the guidelines will need to be updated as more data become available about the long‐term effectiveness of ETI in advanced lung disease.

Subjects

MeSH terms (MEDLINE)

Cystic FibrosisLung TransplantationBenzodioxolesReferral and ConsultationDrug CombinationsPyridinesPyrazolesIndolesAminophenolsQuinolonesHumansSurveys and QuestionnairesUnited StatesPyrrolidinesPractice Patterns, Physicians'FemaleMaleAttitude of Health PersonnelPhysiciansQuinolines

Author keywords

cystic fibrosiselexacaftor/tezacaftor/ivacaftorlung transplantationphysician surveyreferral

Substances

BenzodioxolesDrug CombinationsPyridinesPyrazolesIndolesAminophenolsQuinolonesPyrrolidineselexacaftor, ivacaftor, tezacaftor drug combinationQuinolines

Authors and institutions

  • Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Medicine, University of Washington, Seattle, Washington, USA.
  • Cystic Fibrosis Foundation, Bethesda, Maryland, USA.
  • Division of Pulmonary and Critical Care Medicine, University of California at Los Angeles, Los Angeles, California, USA.
  • Division of Pulmonary and Critical Care Medicine, Columbia University, New York, New York, USA.
  • Division of Pulmonary and Allergy, Department of Pediatrics, University of Washington, Seattle, Washington, USA.
  • Center for Respiratory Biology and Therapeutics, Seattle Children's Research Institute, Seattle, Washington, USA.

ORCID profiles: Nora Burdis

Funding

  • NIH HHS
  • NIDDK NIH HHS
  • Cystic Fibrosis Foundation
  • NHLBI NIH HHS
  • NINR NIH HHS

Cite

APA

Burdis, N., Milinic, T., Bartlett, L. E., Goss, L., Tallarico, E., Boyle, A., Thaxton, A., Turner, G. A., Benvenuto, L. J., Faro, A., Goss, C. H., Kapnadak, S. G., & Ramos, K. J. (2024). A survey of cystic fibrosis physicians' views on lung transplant referral in the era of elexacaftor/tezacaftor/ivacaftor. Pediatric Pulmonology. https://doi.org/10.1002/ppul.27273

Vancouver

Burdis N, Milinic T, Bartlett LE, Goss L, Tallarico E, Boyle A, et al. A survey of cystic fibrosis physicians' views on lung transplant referral in the era of elexacaftor/tezacaftor/ivacaftor. Pediatric Pulmonology. 2024. doi:10.1002/ppul.27273

BibTeX
@article{Burdis2024,
  author = {Burdis, Nora and Milinic, Tijana and Bartlett, Lauren E and Goss, Louisa and Tallarico, Erin and Boyle, Abigail and Thaxton, Abigail and Turner, Grant A and Benvenuto, Luke J and Faro, Albert and Goss, Christopher H and Kapnadak, Siddhartha G and Ramos, Kathleen J},
  title = {A survey of cystic fibrosis physicians' views on lung transplant referral in the era of elexacaftor/tezacaftor/ivacaftor},
  journal = {Pediatric Pulmonology},
  year = {2024},
  doi = {10.1002/ppul.27273}
}
Start for free →